Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX Phase II trial of paclitaxel + bevacizumab vs paclitaxel + capecitabine + bevacizumab in HER2-negative metastatic breast cancer
2006-006058-83Phase 2Active
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Jun 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing paclitaxel + bevacizumab with paclitaxel + capecitabine + bevacizumab (2 arms). Primary endpoint: Progression-free survival. Started Jun 2007; status: active.
02
Drugs
bevacizumabpaclitaxelcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-006058-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006058-83.